Physical exercise and improvement of liver oxidative metabolism in the elderly

European Journal of Applied Physiology and Occupational Physiology

Volumn 81, Issue 1-2, 2000, Pages 62-66

  Mauriz, J L ^a   Tabernero, B ^a   Garcia Lopez J ^a   Jorquera, F ^b   Villa, J G ^a   Gonzalez Gallego J ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b Hospital of Leon   (Spain)

Author keywords

Antipyrine clearance; Elderly; Oxidative metabolism; Physical conditioning

Indexed keywords

CYTOCHROME P450; NORPHENAZONE; PHENAZONE;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SALIVA LEVEL; ENDURANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIVER METABOLISM; METABOLITE; MUSCLE STRENGTH; NORMAL HUMAN; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SENESCENCE; TIME; TRAINING; URINALYSIS;

EID: 0343048984     PISSN: 03015548     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00013798     Document Type: Article

References (36)

1. Allison K, Keller C (1997) Physical activity in the elderly: benefits and intervention strategies. Nurse Pract 22:53-54
2. American College of Sports Medicine (1998) American College of Sports Medicine position stand Exercise and physical activity for older adults. Med Sci Sports Exerc 30:992-1008
3. Bach B, Hansen JM, Kanpmann JP, Rasmussen SN, Skovsted L (1981) Disposition of antipyrine and phenytoin with age and liver volume in man. Clin Pharmacokinet 6:389-396
4. Barthelemy L, Sebert P, Mialon P (1985) Contribution a l'etude de la signification physiologique de l'epreuve de Ruffier-Dickson. Med Sport 61:171-173
5. Boel J, Andersen LB, Rasmussen B, Hansen SH, Dossing M (1984) Hepatic drug metabolism and physical fitness Clin Pharmacol Ther 36:121-126
6. Danhof M, Groot van der Vis E, Breimer DD (1979) Assay of antipyrine and its metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology 18:210-223
7. De Vito G, Bernardi M, Sproviero E, Figura F (1995) Decrease of endurance performance during Olympic triathlon. Int J Sports Med 16:24-28
8. Dossing M, Poulsen HE, Andreasen PB, Tygstrup N (1982) A simple method for determination of antipyrine clearance Clin Pharmacol Ther 32:392-396
9. Ducry JJ, Howald H, Zysset T, Bircher J (1979) Liver function in physically trained subjects galactose elimination capacity, plasma disappearance of indocyanine green and aminopyrine metabolism in long distance runners. Dig Dis Sci 24:192-196
10. Engel G, Hofman U, Hiedemann H, Cosme J, Eichelbaum M (1996) Antipyrine as a probe for human oxidative metabolism identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxynethylantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59:613-623
11. Fabbri A, Bianchi G, Zoli M, Marchi E, Marchesini G (1991) Effect of physical exercise on one-sample antipyrine clearance Ital J Gastroenterol 23:74-76
12. Frenkl R, Gyore A, Meszaros J, Szeberenyi SZ (1980) A study of the enzyme-inducing effect of physical exercise in man. The "trained liver" J Sports Med 20:371-376
13. Jackson AS, Pollock ML (1978) Generalized equations for predicting body density of man. Br J Nutr 40:497-504
14. Jorquera F, Almar M, Pozuelo M, Sansegundo D, González-Sastre M, González-Gallego J (1995) Effects of aging on antipyrine clearance: predictive factors of metabolizing capacity J Clin Pharmacol 35:895-900
15. Jorquera F, Almar M, Pozuelo M, Sansegundo D, González-Sastre M, González-Gallego J (1998) The effect of age and sex on metabolism and urinary excretion of antipyrine. J Gerontol 53:14-19
16. Kohrt WM, Obert KA, Holloszy JO (1992) Exercise improves fat distribution patterns in 60- to 70-year-old men and women J Gerontol Med Sci 47:M99-M105
17. Loft S, Dossing M, Poulsen HE (1988) Influence of age and consumption of tobacco, alcohol and caffeine on antipyrine clearance. Hum Toxicol 7:277-280
18. MacDougall JD, Wenger HA, Green HJ (1991) Physiological testing of the high performance athlete Human Kinetics Champaign, II
19. Mikati MA, Szabo GK, Pylilo RJ (1988) Improved high-performance liquid chromatographic assay of antipyrine, hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine in urine. J Chromatogr 433:305-311
20. O'Malley K, Crooks J, Duke E, Stevenson IH (1971) Effect of age and sex on human drug metabolism. Br Med J 3:607-609
21. Oriolli S, Bardinelli A, Birardi A, Chieca R, Buzelli G, Chiarantini E (1990) Hepatic antipyrine metabolism in athletes J Sports Med 30:261-263
22. Posner J, Danhof M, Teunissen MWE, Breimer DD, Whiteman PD (1987) The disposition of antipyrine and its metabolites in young and elderly healthy volunteers. Br J Clin Pharmacol 124:51-55
23. Poulsen HE, Loft S (1988) Antipyrine as a model drug to study hepatic drug-metabolizing capacity J Hepatol 6:374-382
24. Sharer JE, Wrighton SA (1996) Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine Drug Metab Dispos 24:487-494
25. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M (1997) Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathological conditions Clin Pharmacol Ther 61:331-339
26. St Peter JV, Awni WM (1991) Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinet 20:50-65
27. St Peter JV, Braeckman RA, Granneman GR, Locke CS, Cavanaugh JH, Awni WM (1995) The effect of zileuton on antipyrine and indocyanine green disposition. Clin Pharmacol Ther 57:299-308
28. Swift CG, Homeida M, Halliwel M, Roberts CJC (1978) Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol 14:149-152
29. Tager IB, Hollenberg M, Satariano WA (1998) Association between self-reported leisure-time physical activity and measures of cardiorespiratory fitness in an elderly population. Am J Epidemiol 147:921-931
30. Teunissen MWE, Meerburg-Van der Torren JE, Vermeulen NPE, Breimer D (1983) Automated HPLC determination of antipyrine and its main metabolites in plasma, saliva, and urine, including 4,4′-dihydroxiantipyrine. J Chromatogr 278:367-378
31. Teunissen MWE, Spoelstra, P, Koch CW (1984) Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol 18:707-715
32. Teunissen MWE, Kampf D, Roots I, Vermeulen NPE, Breimer DD (1985) Antipyrine metabolite formation and excretion in patients with chronic renal failure. Eur J Clin Pharmacol 128:589-595
33. Vesell ES, DeAngelo TM, Katz IR (1993) Reproductibility of antipyrine half-lives in elderly subjects Clin Pharmacol Ther 54:150-157
34. Vestal RE, Wood AJJ (1980) Influence of age and smoking on drug kinetics in man. Studies using model compounds Clin Pharmacokinet 5:309-319
35. Villa JG, Cuadrado G, Bayón JE, González-Gallego J (1998) The effect of physical conditioning on antipyrine metabolism Eur J Appl Physiol 77:106-111
36. Ziegler DM (1994) Detoxication, oxidation and reduction In Arias IM, Boyer JL, Fausto N, et al (eds) The liver: biology and pathobiology. Raven, New York pp 415-428